Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4ce868b9e53b7acdb989834eb13b394e |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5026 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-138 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5078 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-138 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14 |
filingDate |
2000-01-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b14697f1c314005b9caa9fdbbee5e0c0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c3c45f0f5a544085d8b52d71433bd86a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9c83cd93e04d6bb65eb3c0d850bfe174 |
publicationDate |
2001-05-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-0042998-A9 |
titleOfInvention |
Multiparticulate bisoprolol formulation |
abstract |
A multiparticulate bisoprolol formulation for once-daily oral administration, each particle of which comprises a core of bisoprolol or a pharmaceutically acceptable salt thereof surrounded by a polymeric coating, the polymeric coating being effective to achieve an initial lag of bisoprolol release in vivo of at least 4-6 hours following administration and thereafter maintaining therapeutic concentrations of bisoprolol for the remainder of the twenty-four hour period. The formulation can be used for night-time dosing so as to minimise the likelihood of acute cardiovascular occurrences in the well-documented high risk period in the morning. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9161918-B2 |
priorityDate |
1999-01-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |